pramipexol (pramipexole)

Subscribe to Selected New Research on pramipexol

270 relevant articles (56 outcomes, 81 trials/studies) found for this Drug

Description: RN given refers to (S)-isomer

Also Known As:

pramipexole; Mirapex; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole; 4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine; KNS 760704; KNS-760704; KNS760704; SND 919CL2x; SND-919; SND-919CL2x; SND919CL2x; pramipexol dihydrobromide, (+-)-isomer; pramipexol dihydrochloride, (S)-isomer; pramipexol, (+-)-isomer; pramipexol, (R)-isomer; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 25

1-Ring Heterocyclic Compounds

2-Ring Heterocyclic Compounds

Benzothiazoles: 10

pramipexol: 270

Experts

1.	Parkinson Study Group: 7 articles (03/2007 - 10/2000)
2.	Koester, Juergen: 6 articles (07/2008 - 01/2005)
3.	Oertel, Wolfgang H: 6 articles (06/2007 - 01/2004)
4.	Holloway, Robert G: 5 articles (01/2006 - 02/2002)
5.	Reess, Juergen: 4 articles (07/2008 - 08/2006)
6.	Stiasny-Kolster, Karin: 3 articles (01/2007 - 01/2004)
7.	Montplaisir, J: 3 articles (12/2006 - 05/2000)
8.	Reichmann, Heinz: 3 articles (10/2006 - 01/2003)
9.	Dick, Andrew W: 3 articles (01/2006 - 09/2004)
10.	Noyes, Katia: 3 articles (01/2006 - 09/2004)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 05/01/2005 - "In addition, pramipexole significantly improved the subitems motivation/initiative and depression in a subpopulation with increased Unified Parkinson's Disease Rating Scale I scores at the time of inclusion. " 07/11/1997 - "In the present study, pramipexole, a D3-preferring DA agonist effective in treating Parkinson's disease, excited type II anterior CN neurons. " 07/01/2009 - "OBJECTIVE: To evaluate the impact of the DRD2 TaqIA and DRD3 Ser9Gly polymorphisms on the efficacy of pramipexole in treating patients with Parkinson's disease (PD). " 05/01/2006 - "Despite the absence of motor complications, the pramipexole recipients showed improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore. " 07/09/1997 - "Safety and efficacy of pramipexole in early Parkinson disease. " Order ALL the reference details at left...
2.	Tremor (Tremors) 05/01/2000 - "In another study pramipexole has been shown to be significantly superior to placebo with an improvement in tremor score by 48% (vs. 13% in the placebo group). " 09/01/1999 - "The patients were drawn from a larger placebo-controlled, double-blind, randomized trial, which was not originally designed to investigate the effect of pramipexole on tremor. " 01/01/2006 - "The main reasons for switching to pramipexole (anti-tremor effect, anti-depressive/anti-anhedonic effect) as given by the physicians at baseline came up to expectations. " 05/01/2005 - "Patients with pronounced resting tremor derived a clear benefit from pramipexole treatment compared with placebo. " 10/01/2003 - "Three weeks after initiation of pramipexol, the tremor artefact was no longer visible on ECG. " Order ALL the reference details at left...
3.	Restless Legs Syndrome (Restless Legs) 01/20/2007 - "Fifty-one patients suffering from idiopathic restless legs syndrome underwent monotherapy with pramipexole in daily doses of 0.25 to 1.0 mg. Therapeutic efficacy was evaluated using three tools, i.e. " 01/15/2007 - "Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)." 03/23/1999 - "Restless legs syndrome improved by pramipexole: a double-blind randomized trial." 08/01/2007 - "First night efficacy of pramipexole in restless legs syndrome and periodic leg movements." 01/15/2007 - "We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks. " Order ALL the reference details at left...
4.	Dyskinesias (Dyskinesia) 07/01/2004 - "RESULTS: Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias (24.5% vs 54%; hazard ratio, 0.37; 95% confidence interval [CI], 0.25-0.56; P<.001) and wearing off (47% vs 62.7%; hazard ratio, 0.68; 95% CI, 0.49-0.63; P =.02). " 04/01/2008 - "This review addresses the literature concerning pramipexole's efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances." 01/01/2008 - "Furthermore, in laboratory studies pramipexole has proved to exert neuroprotector effects and its use in clinical practice from the early stages of the disease has been related to a delay in the appearance of motor complications (fluctuations and dyskinesias). " 01/01/2000 - "No significant changes were noted in a dyskinesia rating scale in any of the 4 studies, but dyskinesia as an adverse event was reported more frequently with pramipexole. " 12/01/2006 - "Pramipexole treatment was associated with later occurrence of dyskinesias. " Order ALL the reference details at left...
5.	Parkinsonian Disorders (Parkinsonism) 05/01/2002 - "Pramipexole 0.25 mg TID improved dramatically the Parkinsonism and all neurological symptoms resolved in a few days." 10/01/2008 - "CONCLUSION: In PD, pramipexole improved parkinsonism but did not modify RBD related symptoms and objective video-polysomnographic abnormalities. " 10/01/2008 - "Pramipexole improved parkinsonism in all patients. " 01/01/2006 - "The results obtained characterize mirapex as a drug of choice in the treatment of juvenile parkinsonism. " 10/01/2008 - "MEASUREMENTS AND RESULTS: In a prospective study, 11 consecutive PD patients with untreated RBD on levodopa monotherapy were placed on pramipexole to further ameliorate their parkinsonism. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Dopamine Agonists (Dopamine Agonist)
3.	ropinirole (Requip)
4.	Pergolide (Permax)
5.	cabergoline
6.	Dopamine (Intropin)
7.	N 0437
8.	Bromocriptine (Parlodel)
9.	Dopamine Receptors (Dopamine Receptor)
10.	Antidepressive Agents (Antidepressants)

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Analgesia
3.	Renal Dialysis (Hemodialysis)
4.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Parkinson Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1228 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>